Ontology highlight
ABSTRACT:
SUBMITTER: Caldarola G
PROVIDER: S-EPMC9287013 | biostudies-literature | 2022 Jun
REPOSITORIES: biostudies-literature
Caldarola Giacomo G Galluzzo Marco M Bernardini Nicoletta N Calabrese Laura L Grimaldi Marta M Moretta Gaia G Pagnanelli Gianluca G Shumak Ruslana Gaeta RG Talamonti Marina M Tofani Lorenzo L Pallotta Sabatino S Peris Ketty K Potenza Concetta C De Simone Clara C Campione Elena E
Dermatologic therapy 20220411 6
New biologic agents targeting interleukin (IL)23/T-helper17 axis, such as tildrakizumab, have been developed for the treatment of plaque psoriasis. To analyze the efficacy and safety of tildrakizumab in a real life setting of patients affected by moderate-to-severe psoriasis over a 28-week treatment period. A multicentric retrospective study was conducted in patients who initiated tildrakizumab between February 2020 and March 2021. Psoriasis Area and Severity Index-PASI was measured at baseline ...[more]